Genelux Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 26

Employees

  • Stock Symbol
  • GNLX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.16
  • (As of Friday Closing)

Genelux General Information

Description

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Contact Information

Website
www.genelux.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2625 Townsgate Road
  • Suite 230
  • Westlake Village, CA 91361
  • United States
+1 (805)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 2625 Townsgate Road
  • Suite 230
  • Westlake Village, CA 91361
  • United States
+1 (805)

Genelux Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genelux Stock Performance

As of 20-Nov-2026, Genelux’s stock price is $2.16. Its current market cap is $103M with 47.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.16 $2.28 $1.77 - $5.89 $103M 47.6M 332K -$0.88

Genelux Financials Summary

As of 30-Sep-2026, Genelux has a trailing 12-month revenue of $8K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 98,221 147,615 49,492 346,342
Revenue 8 8 8 170
EBITDA (38,191) (32,640) (30,423) (26,701)
Net Income (37,932) (32,145) (29,869) (28,297)
Total Assets 20,612 19,027 34,716 27,893
Total Debt 2,344 1,685 1,868 2,519
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Genelux Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Genelux‘s full profile, request access.

Request a free trial

Genelux Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Genelux‘s full profile, request access.

Request a free trial

Genelux Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. It
Drug Discovery
Westlake Village, CA
26 As of 2025

Boston, MA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Genelux Competitors (72)

One of Genelux’s 72 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Boston, MA
Sutro Biopharma Formerly VC-backed South San Francisco, CA
ORIC Pharmaceuticals Formerly VC-backed South San Francisco, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Oncorus Formerly VC-backed Andover, MA
You’re viewing 5 of 72 competitors. Get the full list »

Genelux Patents

Genelux Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2023544184-A Bioreactor generation of viruses from adherent cells Inactive 02-Oct-2020
EP-4222250-A1 Bioreactor production of virus from adherent cells Pending 02-Oct-2020
JP-2025118611-A Bioreactor production of virus from adherent cells Pending 02-Oct-2020
WO-2022071966-A1 Bioreactor production of virus from adherent cells Inactive 02-Oct-2020
US-10851350-B1 Bioreactor production of virus from adherent cells Active 27-Jun-2017 C12N7/02
To view Genelux’s complete patent history, request access »

Genelux Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genelux Investments (1)

Genelux’s most recent deal was a Joint Venture with V2ACT Therapeutics. The deal was made on 01-Jan-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
V2ACT Therapeutics 01-Jan-2019 Joint Venture Drug Discovery
To view Genelux’s complete investments history, request access »

Genelux ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

40.3 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Genelux’s complete esg history, request access »

Genelux FAQs

  • When was Genelux founded?

    Genelux was founded in 2001.

  • Where is Genelux headquartered?

    Genelux is headquartered in Westlake Village, CA.

  • What is the size of Genelux?

    Genelux has 26 total employees.

  • What industry is Genelux in?

    Genelux’s primary industry is Drug Discovery.

  • Is Genelux a private or public company?

    Genelux is a Public company.

  • What is Genelux’s stock symbol?

    The ticker symbol for Genelux is GNLX.

  • What is the current stock price of Genelux?

    As of 20-Nov-2026 the stock price of Genelux is $2.16.

  • What is the current market cap of Genelux?

    The current market capitalization of Genelux is $103M.

  • What is Genelux’s current revenue?

    The trailing twelve month revenue for Genelux is $8K.

  • Who are Genelux’s competitors?

    Aura Biosciences, Sutro Biopharma, ORIC Pharmaceuticals, Adaptimmune Therapeutics, and Oncorus are some of the 72 competitors of Genelux.

  • What is Genelux’s annual earnings per share (EPS)?

    Genelux’s EPS for 12 months was -$0.88.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process